Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

Background:P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.Methods:Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian–Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.Results:A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33–1.61 for p53; HR 1.65, 95% CI 1.25–2.19 for EGFR and HR 1.67, 95% CI 1.34–2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.Conclusions:Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies.

• Publication year

  2009

• Venue

  British Journal of Cancer

• Publication date

  2009-06-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.bjc.6605112PMID 19513073PMCID 2713689
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.

  2008cited by this paper
• Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.

  2008influential reference
• Epidermal Growth Factor Receptor Expression in Serous Ovarian Carcinoma: An Immunohistochemical Study With Galectin-3 and Cyclin D1 and Outcome

  2008cited by this paper
• Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.

  2008cited by this paper
• New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.

  2008cited by this paper
• Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

  2008influential reference
• Prognostic versus predictive value of biomarkers in oncology.

  2008cited by this paper
• The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer

  2008cited by this paper
• Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

  2008influential reference
• Decreased survival in EGFR gene amplified vulvar carcinoma.

  2008cited by this paper
• Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma

  2008cited by this paper
• Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival

  2008cited by this paper
• HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

  2007cited by this paper
• Combination of serum hCGβ and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma

  2007cited by this paper
• Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.

  2007influential reference
• In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway

  2007cited by this paper
• Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.

  2007cited by this paper
• Adenomyosis is Associated With Myometrial Invasion by FIGO 1 Endometrial Adenocarcinoma

  2007cited by this paper
• Epidermal Growth Factor Receptor Is Involved in the Development of an Invasive Phenotype in Vulvar Squamous Lesions, but Is Not Related to MIB-1 Immunoreactivity

  2007cited by this paper
• Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients.

  2007cited by this paper
• Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas

  2007cited by this paper
• Linking oncogenic pathways with therapeutic opportunities

  2006cited by this paper
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cited by this paper
• Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples.

  2006cited by this paper
• Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.

  2006influential reference
• Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).

  2006cited by this paper
• Bmc Medical Research Methodology Open Access Intra-cluster Correlation Coefficients in Adults with Diabetes in Primary Care Practices: the Vermont Diabetes Information System Field Survey

  2006cited by this paper
• Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.

  2006cited by this paper
• The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

  2006cited by this paper
• Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets.

  2006cited by this paper
• Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

  2006cited by this paper
• Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer

  2006cited by this paper
• Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

  2006cited by this paper
• Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

  2005cited by this paper
• Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.

  2005influential reference
• The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer

  2005cited by this paper
• REporting recommendations for tumour MARKer prognostic studies (REMARK)

  2005cited by this paper
• REporting recommendations for tumour MARKer prognostic studies (REMARK)

  2005cited by this paper
• Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

  2005cited by this paper
• HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

  2005cited by this paper
• Prognostic factors in ovarian cancer: how close are we to a complete picture?

  2005cited by this paper
• Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression

  2005cited by this paper
• Retinoid receptors in ovarian cancer: expression and prognosis.

  2005cited by this paper
• Origins and molecular pathology of ovarian cancer

  2005cited by this paper
• Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary.

  2005cited by this paper
• Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary.

  2005cited by this paper
• Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo

  2005cited by this paper
• Correlation of Epidermal Growth Factor Receptor Expression with Tumor Microdensity Vessels and with Vascular Endothelial Growth Factor Expression in Ovarian Carcinoma

  2005cited by this paper
• Expression of the c‐myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer

  2004cited by this paper
• Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer

  2004cited by this paper
• ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.

  2004cited by this paper
• HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.

  2004cited by this paper
• Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?

  2004cited by this paper
• Critical evaluation of p53 as a prognostic marker in ovarian cancer

  2004cited by this paper
• Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.

  2004cited by this paper
• Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)

  2004cited by this paper
• P53 Expression, Dna Ploidy and Mitotic Index as Prognostic Factors in Patients with Epithelial Ovarian Carcinoma

  2004cited by this paper
• Multivariate analysis for prognostic significance of histologic subtype, GST‐pi, MDR‐1, and p53 in stages II‐IV ovarian cancer

  2003cited by this paper
• Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins

  2003cited by this paper
• Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer

  2003influential reference
• Prognostic factors in ovarian cancer: current evidence and future prospects

  2003cited by this paper
• Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2003influential reference
• Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients.

  2003cited by this paper
• Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours.

  2003cited by this paper
• Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Heterogeneity of Ovarian Cancer: Relationships Among Histological Group, Stage of Disease, Tumor Markers, Patient Characteristics, and Survival

  2002cited by this paper
• P53 and Bcl‐2 as prognostic predictors in epithelial ovarian cancer

  2002cited by this paper
• Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.

  2002cited by this paper
• How should meta‐regression analyses be undertaken and interpreted?

  2002cited by this paper
• Prognostic value of p53 accumulation in epithelial ovarian carcinomas

  2002cited by this paper
• Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

  2001cited by this paper
• P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma

  2001influential reference
• Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.

  2001cited by this paper
• Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

  2001cited by this paper
• Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

  2001cited by this paper
• Possible associations among expression of p14ARF, p16INK4a, p21WAF1/CIP1, p27KIP1, and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas

  2001cited by this paper
• Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.

  2000cited by this paper
• The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

  2000cited by this paper
• E-Cadherin complex protein expression and survival in ovarian carcinoma.

  2000cited by this paper
• Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival

  2000cited by this paper
• Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer.

  2000cited by this paper
• Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas

  2000cited by this paper
• p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.

  2000cited by this paper
• The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

  2000influential reference
• Prognostic Factors in Early‐Onset Epithelial Ovarian Cancer: A Population‐Based Study

  2000cited by this paper
• c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.

  1999cited by this paper
• Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer.

  1999cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer.

  1999cited by this paper
• p53 mutations and expression in ovarian cancers: correlation with overall survival.

  1999cited by this paper
• Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.

  1999cited by this paper
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

  1999cited by this paper
• Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

  1998cited by this paper
• Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer.

  1998cited by this paper
• Bias in meta›analysis detected by a simple, graphical test

  1998cited by this paper
• Expression of p53 protein in borderline epithelial ovarian tumors: a clinicopathologic study of 39 cases.

  1998influential reference
• The clinical predictivity of biomarkers of stage III‐IV epithelial ovarian cancer in a prospective randomized treatment protocol

  1998cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper

• Cannabinoids as Promising Inhibitors of HER2-Tyrosine Kinase: A Novel Strategy for Targeting HER2-Positive Ovarian Cancer

  2025cites this paper
• P53 marker expression in epithelial ovarian tumours in a centre in Nigeria – a descriptive study

  2024cites this paper
• The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers

  2023cites this paper
• Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance.

  2023cites this paper
• A fluorescent photoimmunoconjugate for imaging of cholesteatoma

  2022cites this paper
• Identification of EGFR-Related LINC00460/mir-338-3p/MCM4 Regulatory Axis as Diagnostic and Prognostic Biomarker of Lung Adenocarcinoma Based on Comprehensive Bioinformatics Analysis and Experimental Validation

  2022cites this paper
• Immunohistochemical expression of P53 and Ki-67 on epithelial tumors of ovary

  2021cites this paper
• An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear

  2021cites this paper
• Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.

  2020cites this paper
• ABO Blood Groups Associations with Ovarian Cancer: A Systematic Review and Meta-analysis

  2020cites this paper
• Predictive and Prognostic Relevance of p53 in Patients With Serous Epithelial Ovarian Cancer

  2020influential citation
• Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer

  2020cites this paper
• Association of CD31 and p53 With Survival of Ovarian Cancer Patients

  2019cites this paper
• AB0 Blood Group and Ovarian Cancer Survival

  2019cites this paper
• C-ERB-2, P53, Ki67 Proteins and Receptors of Estrogen and Progesterone on the Prognosis of Epithelial Ovarian Cancer

  2019cites this paper
• The prognostic value of anterior commissure involvement in T1 glottic cancer: A systematic review and meta‐analysis

  2019cites this paper
• Antrodia salmonea‐induced oxidative stress abrogates HER‐2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells

  2018cites this paper
• Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer

  2018cites this paper
• Cancer molecular markers: A guide to cancer detection and management.

  2018cites this paper
• Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing

  2018cites this paper
• Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta‐analysis

  2018cites this paper
• Improving the understanding of platinum sensitivity and the tumour microenvironment in high grade serous ovarian cancer

  2018influential citation
• Genomic Applications in Ovarian Cancer

  2018cites this paper
• Prognostic Value of HER-2/neu Gene Amplification in Epithelial Ovarian Carcinoma

  2018cites this paper
• Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer

  2018cites this paper
• EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review

  2017cites this paper
• Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

  2017cites this paper
• FoxM1: Repurposing an oncogene as a biomarker.

  2017cites this paper
• Tumor-infiltrating immune cells and prognosis in gastric cancer: a systematic review and meta-analysis

  2017cites this paper
• Molecular mechanisms underlying the action of histone deacetylases inhibitors (HDACIs) in ovarian cancer

  2017cites this paper
• Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.

  2017cites this paper
• TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer

  2017cites this paper
• Prognostic roles of Notch receptor mRNA expression in human ovarian cancer

  2017cites this paper
• The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis

  2016cites this paper
• Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC

  2016cites this paper
• Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis

  2016cites this paper
• The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I–II

  2016cites this paper
• High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer

  2016cites this paper
• Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

  2016cites this paper
• Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing

  2016cites this paper
• Prognostic value of hedgehog signaling pathway in digestive system cancers: A systematic review and meta-analysis

  2016cites this paper
• p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer

  2016cites this paper
• The prognostic significance of HOTAIR for predicting clinical outcome in patients with digestive system tumors

  2015cites this paper
• Role of HER Family Members in Predicting Prognoses in Epithelial Ovarian Cancer: A Meta-analysis

  2015cites this paper
• HER2 expression in gastric and oesophageal cancer: a meta-analytic review.

  2015cites this paper
• Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma

  2015cites this paper
• Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis

  2015cites this paper
• Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis

  2015cites this paper
• Extracapsular Extension of Pelvic Lymph Node Metastasis is an Independent Prognostic Factor in Bladder Cancer: A Systematic Review and Meta-analysis

  2015cites this paper
• Potential impact of (rs 4645878) BAX promoter −248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients

  2015cites this paper
• Predicting survival in head and neck squamous cell carcinoma from TP53 mutation

  2015cites this paper
• Genomic Applications in Epithelial Ovarian Malignancies

  2015cites this paper
• Microvascular invasion as a prognostic indicator in renal cell carcinoma: a systematic review and meta-analysis.

  2015cites this paper
• Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis

  2015cites this paper
• Prognostic significance of matrix metalloproteinase 7 immunohistochemical expression in colorectal cancer: a meta-analysis.

  2015cites this paper
• BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer

  2015cites this paper
• Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.

  2015cites this paper
• Prognostic Significance of Lymphovascular Invasion in Radical Cystectomy on Patients with Bladder Cancer: A Systematic Review and Meta-Analysis

  2014cites this paper
• Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis

  2014cites this paper
• Lack of effects of HER-2/neu on prognosis in colorectal cancer: a meta-analysis.

  2014cites this paper
• Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis

  2014cites this paper
• Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma

  2014cites this paper
• Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis.

  2014cites this paper
• Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?

  2014cites this paper
• Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.

  2014cites this paper
• Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis.

  2014cites this paper
• 14 P 53 Network in Ovarian Cancer

  2014cites this paper
• The chicken model of ovarian cancer: A novel TP53 mRNA variant found in healthy and cancerous tissue

  2014cites this paper
• Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis

  2013cites this paper
• The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.

  2013cites this paper
• Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.

  2013cites this paper
• Association of p 21 , p 21 p 27 and p 21 p 53 Status to Histological Subtypes and Prognosis in Low-stage Epithelial Ovarian Cancer

  2013cites this paper
• Tumor markers in finding recurrent disease in colorectal cancer: a diagnostic review

  2013cites this paper
• The anti-cancer activity of Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells via modulation of HER-2/neu signaling pathway.

  2013cites this paper
• Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.

  2013cites this paper
• Poor survival with wild-type TP53 ovarian cancer?

  2013cites this paper
• Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies

  2013cites this paper
• P53 Network in Ovarian Cancer

  2012cites this paper
• The N-Terminally Truncated p53 Isoform &Dgr;40p53 Influences Prognosis in Mucinous Ovarian Cancer

  2012cites this paper
• Factors affecting response of chemotherapy in women with ovarian cancer.

  2012cites this paper
• P53 and Ki67 immunoexpression in mucinous malignant ovarian tumors.

  2012cites this paper
• Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review

  2012cites this paper
• Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

  2012cites this paper
• Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile: A Phase 2 Trial

  2012cites this paper
• Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma.

  2012cites this paper
• Utilisation of search filters in systematic reviews of prognosis questions.

  2012cites this paper
• In search of new prognostic molecular markers in ovarian cancer

  2012cites this paper
• Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2

  2012cites this paper
• Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma

  2012cites this paper
• The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

  2011cites this paper
• The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.

  2011cites this paper
• Molecular Pathology of Ovarian Carcinomas.

  2011cites this paper
• Surface Epithelial Tumors: Pathology Introduction

  2011cites this paper
• Meta-analysis of the prognostic role of p53: Playground for solution or source of confusion?

  2011cites this paper
• Emerging therapeutic targets in ovarian cancer

  2011cites this paper
• Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

  2011cites this paper
• New Insights into Tubulin Binders

  2011cites this paper
• Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

  2011cites this paper
• An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas

  2011cites this paper
• Intraoperative Imaging in Ovarian Cancer: Fact or Fiction?

  2011cites this paper